Robert Dwyer McQuade
Independent Non Executive DirectorDr. Robert Dwyer McQuade, Ph.D., also known as Bob, has been an Independent Director of Camurus AB (publ) since May 27, 2025. He is an Independent Non Executive Director at COMPASS Pathways plc since August 20, 2020. He serves as Executive Vice President & Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC). He serves as the Chief Strategic Officer and Executive Vice President at Otsuka America Pharmaceutical, Inc. Dr. McQuade is President of the McQuade Center for Strategic Research and Development (MSRD) since 2020. He served as an Executive Vice President of Global Medical, Regulatory Affairs & Alliances at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. McQuade served as the Senior Vice President of Global Medical Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. McQuade serves as Vice President of Global Scientific Affairs for the Global Development and Commercialization Office of Otsuka America Pharmaceuticals Inc. Dr. McQuade has over 20 years of pharmaceutical experience in the discovery, development and marketing of drugs for the treatment of mental illness. He began his career at Schering-Plough Pharmaceuticals, where his research focused on the discovery of new drugs for the treatment of schizophrenia and Alzheimer’s disease. He extensively involved in the Neuroscience Licensing Team and Neuroscience STAT (cross-functional team responsible for guiding Neuroscience franchise). Dr. McQuade served as Senior Director of Neuroscience Global Medical Affairs and led the medical affairs team responsible for the collaboration with Otsuka and the development of aripiprazole. He was a key member of the team in the approval process, both in the US and abroad. He has authored numerous publications and posters on aripiprazole. He advanced through a number of positions, culminating in his role as Associate Director of CNS Pharmacology, where he supervised the department of CNS pharmacology, including the biochemistry/ molecular biology and in vivo behavioral sections. Subsequently, he moved to Bristol-Myers Squibb Co. in the department of Global Medical Affairs, where he was responsible for the global medical affairs of the antidepressant, nefazodone (Serzone), the anxiolytic, buspirone (Buspar) and more recently the antipsychotic, aripiprazole (Abilify). Dr. McQuade is a Director of Astex Pharmaceutical, Inc., Astex Pharmaceutical, Ltd., Avanir Pharmaceuticals, Visterra, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., Medical University of South Carolina Foundation for Research and Development, The Technology Accelerator Co. and Clinical Biotechnology Research Institute. He served as Member of Scientific Advisory Board of Galenea Corp. Dr. McQuade received his B.S. degree in Biology from Davidson College (Davidson NC) since 1975 until 1979 and his Ph.D. from the University of North Carolina in Biochemical Pharmacology and biochemistry since 1979 until 2005.
Positions
- Company NameCOMPASS Pathways plcStock CodeCMPSPositionIndependent Non Executive DirectorColleagues
- KKKabir Kumar NathCEO & Executive Director
- GSGino SantiniIndependent Chairman
- TLTeri LoxamChief Financial Officer
- GGGuy GoodwinChief Medical Officer
- SDStephen D. SchultzSenior Vice President of Investor Relations
- KBKelley BoucherChief People Officer
- DKDaphne KarydasIndependent Director
- DYDavid York NortonIndependent Director
